You are here
FDA Accepts New Drug Application for Zegerid Capsules
"We believe that GERD patients may find our immediate-release capsules convenient for daily use and, subject to regulatory approval, commercialization of this formulation could broaden ZEGERID usage," said Gerald T. Proehl, president and chief executive officer of Santarus. "Acceptance of our ZEGERID Capsules NDA submission is an important step in reaching our goal to expand the ZEGERID product family. We plan to offer three product formulations of immediate-release ZEGERID, including powder for oral suspension, capsules and chewable tablets."
Santarus is currently marketing ZEGERID Powder for Oral Suspension 40 mg and 20 mg, an immediate-release PPI product which is rapidly absorbed (reaching peak plasma levels in approximately 30 minutes) and provides strong 24-hour acid control with once daily dosing.
In connection with the FDA's acceptance for filing of the ZEGERID Capsules NDA, Santarus provided notice to the NDA holder for Prilosec(R) delayed-release omeprazole capsules and related patent holders that ZEGERID Capsules 40 mg and 20 mg do not infringe the patents listed in the Orange Book for Prilosec or that those patents are invalid.
Source: Santarus, Inc.